The burden of cancer is increasing rapidly, including in Australia, partly because of ageing populations, reduced competing mortality from cardiovascular disease, and changes in exposure to risk factors for cancer. A further contributor is overdiagnosis, or the diagnosis of cancer in people who would never have experienced symptoms or harm had the cancer remained undetected and untreated. Overdiagnosis of certain screen-detected cancers is common, including 20–50% of prostate cancers and 11–19% of breast cancer diagnoses.

Cancer can also be overdiagnosed outside screening programs. Overdiagnosis of thyroid cancer is attributable to incidental detection during investigations of unrelated problems, overdiagnosis of renal cancer and melanoma is less well investigated.

Overdiagnosis is important because of the associated iatrogenic harms and costs. Harms include the psychosocial impact of unnecessary cancer diagnoses, such as the increased suicide risk for men after being diagnosed with prostate cancer. Cancer treatments such as surgery, radiotherapy, endocrine therapy, and chemotherapy can cause physical harm, but the risks are considered acceptable if diagnosis is appropriate. When someone is unnecessarily diagnosed with cancer, however, they can only be harmed by treatment, not helped.

Concerns about the overdiagnosis and overtreatment of cancer have led to calls to investigate the problem. To facilitate the evaluation of interventions for reducing overdiagnosis, we estimated overdiagnosis levels in Australia for five of the seven cancers for which overdiagnosis has been documented: melanoma, and breast, prostate, thyroid and renal cancers. Neuroblastoma was not included because neuroblastoma screening is not undertaken in Australia, and lung cancer was excluded because declines in smoking rates and the unquantified uptake of screening complicate the assessment of overdiagnosis.

**Methods**

We aimed to estimate the proportion of cancer diagnoses in Australia that might reasonably be attributed to overdiagnosis by calculating and comparing current and past lifetime risks of cancer, a method we developed for assessing prostate cancer overdiagnosis.
early detection in preventing clinical presentation at an older age would be apparent. The AIHW data we analysed included only diagnoses of primary cancer, and only the first such diagnosis for a cancer type in an individual, consistent with international practice.

We estimated lifetime risks using the Devcan 6.7.6 software of the United States National Cancer Institute (https://surveillance.cancer.gov/devcan). Devcan applies the statistical methods described by Fay and colleagues, estimating lifetime risk by summing the estimated probabilities of all cancers-specific diagnoses for each age group, adjusted for the competing risk of dying from other causes. We analysed data by 5-year age group (0–85 years, and 85 years or more). To account for changes in mortality between 1982 and 2012, we applied the 2012 mortality distribution (cancer-specific and all-cause mortality data) to the 1982 cancer incidence data, increasing the estimated lifetime risk of a cancer diagnosis in 1982 to reflect the general increase in longevity between 1982 and 2012. The proportion (percentage) of cancers deemed to have been overdiagnosed was estimated as:

\[
100 \times \frac{P(2012) - P(1982)}{P(2012)}
\]

where \( P_Y \) = lifetime probability of cancer diagnosis in year Y.

To estimate 95% confidence intervals (CIs) for our estimates of numbers overdiagnosed, we assumed Poisson distributions for the population estimates of cancers in 2012 and 1982. For example: for prostate cancer, as the number of cancers in 2012 was 20,759 and the estimated number in 1982 was 12,123, the estimated number of overdiagnoses was 8636 and the standard error \( \sqrt{(20,759 + 12,123)} \), or 181.3; the 95% CI was consequently 8636 ± 1.96 × 181.3 (or 8281–8991).

Adjusting for in situ cancers and changed prevalence of risk factors

For breast cancer, we adjusted the 1982 lifetime risk for changes in the prevalence of risk factors (primarily changes in reproductive factors) between 1982 and 2012. An adjustment factor was calculated from changes in the probability of diagnosis in women under 45 years of age, assuming that any changes in this age group would not be substantially affected by screening:

\[
(P_{c45, 2012} - P_{c45, 1982}) / P_{c45, 1982}
\]

where \( P_{c45, Y} \) = probability of breast cancer diagnosis in women under 45 in year Y. We applied this adjustment factor to the lifetime probability of a breast cancer diagnosis (including in situ cancers) in 1982 to estimate the lifetime probability of breast cancer diagnosis in 1982, assuming 2012 risk factor levels.

For melanoma, we multiplied the 1982 lifetime risk by 1.126 for women and by 1.101 for men to account for the in situ cancers likely to have been diagnosed but not recorded in registries. We then multiplied these estimates by an adjustment factor for changes in cumulative sun exposure between 1982 and 2012, using two methods:

• as a sensitivity analysis, adjusted according to changes in mortality from 1975–79 to 1985–89.

The final adjustment factors for our primary method (thick melanomas) were:

\[
\text{Women: } P_{1982} \times 1.126 \times 1.027^{12} \times 1.007^{17} = P_{1982} \times 1.748
\]

\[
\text{Men: } P_{1982} \times 1.101 \times 1.043^{12} \times 1.011^{17} = P_{1982} \times 2.198
\]

We applied these adjustment factors to the lifetime probability of a melanoma diagnosis (including in situ cancers) in 1982 to estimate the lifetime probability of melanoma diagnosis in 1982, assuming 2012 risk factor levels.

Total excess lifetime risk of cancer (overdiagnosis)

To estimate the proportion of all cancer diagnoses in 2012 that might reasonably be deemed overdiagnosed, we first estimated the numbers of overdiagnosed breast, prostate, renal, thyroid cancers and melanoma (total number of specific cancer diagnoses multiplied by estimated overdiagnosis proportion for each cancer) and divided the sum of these estimates by the total number of cancer diagnoses of any type. We assumed that other cancer types were not overdiagnosed.

Other invasive cancers

In a further analysis, we estimated the change in risk of other invasive cancers (ie, invasive cancers other than prostate, breast, renal, thyroid cancers and melanoma) between 1982 and 2012 by subtracting the combined lifetime probability of the five specific invasive cancers from the overall lifetime probability of any invasive cancer, then applying the formula for deriving the proportion of cancers deemed to have been overdiagnosed.

Sensitivity analyses

For breast cancer, we repeated our calculations with different age criteria (< 40 years, < 50 years). For melanoma, we applied an alternative adjustment for changes in the incidence of risk factors (eg, ultraviolet radiation exposure), based on changes in melanoma mortality between 1975–79 and 1985–89, during which period a beneficial effect of informal screening was unlikely.

Potential effects of changes in body mass index

For breast, prostate, renal, and thyroid cancers, we estimated the expected impact of obesity by including estimates of changes in relative risk with increasing body mass index (BMI), based on Australian mean BMI data.

Ethics approval

In this negligible risk research study, we analysed publicly available datasets of non-identifiable aggregated data, and our investigation was therefore exempt from formal ethics review.

Results

Cancer diagnoses in women

The absolute lifetime risk of diagnosis increased between 1982 and 2012 by 3.4 percentage points for breast cancer (invasive
breast cancer, 1.7 percentage points), 0.6 percentage point for renal cancer, 1.0 percentage point for thyroid cancer, and 5.1 percentage points for melanoma (invasive melanoma, 0.7 percentage point). We estimated that 22% of breast cancers (invasive breast cancer, 13%), 58% of renal cancers, 73% of thyroid cancers, and 54% of melanomas (invasive melanoma, 15%) were overdiagnosed, or 18% of all cancer diagnoses in women in 2012 (8% of all invasive cancer diagnoses) (Box 1).

The lifetime absolute risk of any invasive cancer for men increased by 8.6 percentage points (Box 2). Overdiagnosis of invasive breast, renal, thyroid cancer and melanoma explained 47% of this increase. The remaining 53% was explained by increases in other invasive cancers (most notably, the 3.8 percentage point increase in lifetime risk of lung cancer; Supporting Information, table 1).

Cancer diagnoses in men

The absolute lifetime risks of being diagnosed with cancer increased by 8.2 percentage points for prostate cancer, 0.8 percentage point for renal cancer, 0.4 percentage point for thyroid cancer, and 8.0 percentage points for melanoma (invasive melanoma, 1.5 percentage points). We estimated that 42% of prostate cancers, 42% of renal cancers, 73% of thyroid cancers, and 58% of melanomas (22% of invasive melanomas) were overdiagnosed, or 24% of all cancer diagnoses in men in 2012 (16% of all invasive cancer diagnoses) (Box 3).

The absolute lifetime risk of any invasive cancer increased by 10.9 percentage points (Box 2). Overdiagnosis of invasive prostate, renal, and thyroid cancers and of melanoma explained 97% of this increase.

Sensitivity analyses

Estimates of breast cancer overdiagnosis after adjusting for increased breast cancer incidence in women under 40, 45, or 50 years of age ranged between 16% and 28% when including ductal carcinomas in situ, and between 6% and 19% for invasive cancers (Supporting Information, table 2). Estimates for invasive melanoma overdiagnosis adjusted for earlier trends in mortality (instead of concurrent trends in thick lesions) were 5 percentage points higher for both men and women (Supporting Information, table 3).

Potential effects of changes in body-mass index

The risk of post-menopausal breast cancer has been reported to increase by 12% per 5 kg/m2 rise in BMI,23 from 1989 to 2012, the mean BMI for Australian women increased by 1.8 kg/m2.27 Consequently, the expected increase in postmenopausal breast cancers would be 1.12 × 1.8/5 or 1.04, a 4% relative increase; and the overdiagnosis rate would be smaller: about 19% (100 × [0.153 – 0.119 × 1.04]/0.153) rather than 22%.

For prostate cancer, the UK Biobank study24 found that relative risk for prostate cancer declined by 10% per 5 kg/m2 rise in BMI, although it noted that the finding might be explained by prostate-specific antigen being assessed less frequently in obese men. Were this estimate used for the expected change in lifetime probability, overdiagnosis would be greater than the 42% we report.

For renal cancer, the relative risk has been reported to increase by 56% per standard deviation rise in BMI, but this finding may have been influenced by investigation rates.25 Based on changes in mean BMI in Australia from 1989 to 2012,27 this yields relative risks of 1.56 × 1.8/7.5 or 1.13 for women and 1.56 × 1.8/5.2 or 1.19 for men. Were these estimates used for the expected increase in lifetime probability, overdiagnosis rates would be modestly smaller than the 58% (women) and 42% (men) we report.

For thyroid cancer, six of nine studies26 found that thyroid cancer prevalence rose with increasing BMI, but the magnitude of the increase was generally less than that we calculated for renal cancer, so that the impact on estimated overdiagnosis rates would be negligible.

Discussion

We estimated that overdiagnosis accounted for about 18% of cancer diagnoses in women in Australia during 2012, and about

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Lifetime probability of diagnosis</th>
<th>Change in probability, 1982-2012</th>
<th>Overdiagnosis proportion</th>
<th>Cancer diagnoses, 2012</th>
<th>Estimated overdiaagnoses, 2012 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>0.119 0.153</td>
<td>0.034</td>
<td>22%</td>
<td>17 825</td>
<td>3957 (3601–4313)</td>
</tr>
<tr>
<td>Including ductal carcinomas in situ</td>
<td>0.117 0.134</td>
<td>0.017</td>
<td>13%</td>
<td>15 348</td>
<td>1949 (1610–2288)</td>
</tr>
<tr>
<td>Invasive only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>0.044 0.095</td>
<td>0.051</td>
<td>54%</td>
<td>10 492</td>
<td>5634 (5386–5882)</td>
</tr>
<tr>
<td>Including in situ carcinomas</td>
<td>0.039 0.046</td>
<td>0.007</td>
<td>15%</td>
<td>5088</td>
<td>774 (580–968)</td>
</tr>
<tr>
<td>Invasive only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.0038 0.0140</td>
<td>0.0102</td>
<td>73%</td>
<td>1168</td>
<td>851 (774–928)</td>
</tr>
<tr>
<td>Renal</td>
<td>0.0086 0.0110</td>
<td>0.0064</td>
<td>58%</td>
<td>1143</td>
<td>665 (584–746)</td>
</tr>
<tr>
<td>Other invasive cancers</td>
<td>0.290 0.335</td>
<td>0.045</td>
<td>—</td>
<td>32 401</td>
<td>—</td>
</tr>
<tr>
<td>All cancers</td>
<td>0.323 0.365</td>
<td>0.047</td>
<td>—</td>
<td>32 401</td>
<td>—</td>
</tr>
<tr>
<td>Including in situ carcinomas (breast cancer, melanoma)3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive only</td>
<td>0.290 0.335</td>
<td>0.045</td>
<td>—</td>
<td>32 401</td>
<td>—</td>
</tr>
<tr>
<td>Renal</td>
<td>0.0046 0.0086</td>
<td>0.0064</td>
<td>58%</td>
<td>1143</td>
<td>665 (584–746)</td>
</tr>
</tbody>
</table>

The reason for overdiagnosis differs by cancer type. Overdiagnosis of breast cancers is largely attributable to the national screening program, that of prostate cancers and melanoma to opportunistic but extensive screening in Australia. Renal cancer overdiagnosis appears to be largely linked with cancers detected as incidental findings during abdominal imaging for an unrelated reason (incidentalomas). Overdiagnosis of thyroid cancer is related to both incidentalomas and to excessive investigation of thyroid function test abnormalities. Different approaches to reducing rates of overdiagnosis are therefore required for different cancer types.

We recognise that eliminating overdiagnosis altogether is unlikely, but reduction is feasible. For example, the number of thyroid cancer diagnoses in South Korea was reduced by one-third by discouraging ultrasound screening; several countries have reduced prostate cancer incidence and overdiagnosis with more targeted and less frequent prostate screening. However, the potential benefits of changes to early detection practices for breast and prostate cancer, for example, need to be balanced against harms, and clinical and community input should be encouraged. A complementary solution would be tests that identify only clinically important cancers, or at least correctly identify low risk cancers as being such.

Limitations

Despite the robustness of our data — mandatory, national registration of all cancers in Australia since 1982 provided us with a nationally representative longitudinal dataset — our analysis was subject to limitations. First, we assumed no overdiagnosis in 1982, a reasonable assumption given the lower levels of screening. However, the incidence of prostate cancer increased slightly in New South Wales during 1972–1982 without a change in mortality, suggesting some overdiagnosis. Second, we assumed no overdiagnosis of cancers other than the five we specified. The lifetime probability for men of all other invasive cancers increased slightly, and declines for specific cancers (such as lung cancer) may have offset increases in others, some of which may be overdiagnosed. For women, there was a modest increase for other invasive cancers, largely explained by the increased diagnosis of lung cancer (unlikely to be overdiagnosis), but other cancers may have been overdiagnosed. To estimate the total excess risk for all cancers we summed the risks for the individual and other cancers, and for people with more than one type of cancer each was counted separately.

We adjusted for some risk factor changes known to have increased the risk of the included cancers during the period of our study, and we acknowledge the uncertainty inherent in this process. Our adjusted estimate of breast cancer overdiagnosis (22%), however, is consistent with the findings of an independent panel assessment analysing data from randomised trials, and lies in the middle of the range of estimates provided by observational studies. Melanoma overdiagnosis has not been estimated in randomised trials or observational studies, but analysis of population data suggests it is probably substantial and that in situ melanomas account for most overdiagnosed melanomas, consistent with our findings.

Conclusion

Despite the uncertainties in our estimates, the estimated rates of cancer overdiagnosis have important implications for health
policy. First, rates of avoidable overdiagnosis need to be reduced to the lowest level compatible with targeted screening and appropriate investigation. We also need to examine strategies for reducing overtreatment of low risk prostate, breast and thyroid cancers. Our analysis provides a method for deriving baseline estimates of the total burden of cancer overdiagnosis in Australia against which the effectiveness of such interventions could be measured. A second, and perhaps more important implication is that health services need to be alert to new areas of overdiagnosis and to detect them early. This could be an important role for the Australian Institute of Health and Welfare and state cancer registries; increased test, incidence, or treatment rates, without corresponding rises in mortality, could indicate emerging areas of overdiagnosis.

Acknowledgements: We received funding from the Australian National Health and Medical Research Council (NHMRC Fellowship 1080042; Centres of Research Excellence grant 1104136 [Creating sustainable health care: ensuring new diagnostics avoid harms, improve outcomes and direct resources wisely], and Program grant 1103532 [Using healthcare wisely: reducing inappropriate use of tests and treatments]).

Competing interests: No relevant disclosures.

© 2019 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Lifetime probability of diagnosis</th>
<th>Change in probability, 1982-2012</th>
<th>Overdiagnosis proportion</th>
<th>Cancer diagnoses, 2012</th>
<th>Estimated overdiagnoses, 2012 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1982*</td>
<td>2012</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>0.115</td>
<td>0.197</td>
<td>0.082</td>
<td>42%</td>
<td>20 759</td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Including in situ carcinomas</td>
<td>0.059</td>
<td>0.139</td>
<td>0.080</td>
<td>58%</td>
<td>14 436</td>
</tr>
<tr>
<td>Invasive only</td>
<td>0.054</td>
<td>0.069</td>
<td>0.015</td>
<td>22%</td>
<td>7151</td>
</tr>
<tr>
<td>Thyroid</td>
<td>0.0014</td>
<td>0.0052</td>
<td>0.0038</td>
<td>33%</td>
<td>661</td>
</tr>
<tr>
<td>Renal</td>
<td>0.011</td>
<td>0.019</td>
<td>0.008</td>
<td>42%</td>
<td>2045</td>
</tr>
<tr>
<td>Other invasive cancers</td>
<td>0.420</td>
<td>0.423</td>
<td>0.003</td>
<td>—</td>
<td>39 452</td>
</tr>
<tr>
<td>All cancers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Including in situ carcinomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>77 353</td>
</tr>
<tr>
<td>(melanoma)†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70 068</td>
</tr>
</tbody>
</table>

* After applying 2012 mortality age distribution and adjustment for changes in risk factor levels for melanoma. † Change in probability (1982–2012)/probability (2012). ‡ Assuming no overdiagnosis for other cancers.


Supporting Information

Additional Supporting Information is included with the online version of this article.